The women’s health programme developed by the Medicines and Healthcare products Regulatory Agency (MHRA) is multi-faceted, spanning the regulator’s remit in medicines and medical devices, and envisages collaboration with patients, industry and other regulators.
Some of the workstream is focused on identifying where problem areas lie – such as where there are evidence gaps and what the priority areas of unmet need for women are. A range of outputs from the programme are also envisaged, including a new dedicated regulatory framework for female-specific healthcare technologies (femtech), and the development of new guidance to help researchers identify and monitor sex-based differences and to communicate such sex-based differences in outcomes, with the MHRA advocating a “data-driven approach to identifying differences in outcomes to medicines and medical devices between men and women”.
In the medium-term, the regulator said it wants to see greater use of advanced analytics to close data gaps, improved cross-system collaboration on women’s health, and more products meeting the needs of women coming to market, among other things, with the ultimate aim of achieving “more equitable health outcomes”.
Lawrence Tallon, chief executive of the MHRA, said: “Women make up 51% of the population, yet the evidence base that underpins medicines, medical devices and healthcare technologies too often does not reflect women’s lives, bodies or needs. Fewer than 1% of UK clinical trials include pregnant women, only 33% of trials approved from 2019 to 2023 included women of childbearing potential, and women continue to experience differential outcomes in safety, effectiveness and adverse events. These are system-level evidence gaps that shape access, confidence and outcomes across a woman’s life course.”
“Our vision is for a regulatory system that supports equality, actively reduces avoidable evidence gaps, supports innovation where women’s needs remain unmet, and gives women the confidence that healthcare products have been developed and monitored with them in mind. Through this programme, we will work across the UK health system and with international partners to drive lasting improvements in women’s health, reduce inequalities and help set a new benchmark for regulatory leadership in this field,” Tallon added.
Experts in life sciences at Pinsent Masons welcomed the MHRA’s new women’s health programme.
Catherine Drew of Pinsent Masons said: “It is extremely positive for patients that the MHRA recognises the evidence gap and is going further to propose a framework under which that gap will be addressed. This proposal would ensure the MHRA stands alone at the forefront of this field – neither EMA or FDA has a similar workplan – and so again the MHRA is at the forefront as a leading regulator of medicines, as it shown in some other areas too – like where other regulators have followed its lead on removing some regulatory barriers applicable to the development of biosimilars.”
“In terms of specifics, there is mention of the use of real world evidence and other advanced analytical methods to bridge the evidence gap; importantly there is no consideration yet of what additional burdens this is liable to place upon applicants either those wishing to obtain marketing authorisation for their medicines; or those looking to bring medical devices to market in the UK,” she said.
Tracey Roberts of Pinsent Masons said addressing women’s health needs offers a major commercial opportunity for life sciences and healthcare businesses. A recent report by McKinsey, cited by the MHRA, said the UK economy could be boosted by up to £36 billion a year by 2040 if the current health gap is closed.
“The MHRA’s women’s health programme creates opportunities for businesses to lean into this growth area and contribute to plugging the gap,” Roberts said. “The financial rewards could be significant.”
“Previous initiatives have focussed on reproductive health for women. This goes further and includes conditions that affect women disproportionately or differently, such as cardiovascular disease which is the biggest cause of death in women worldwide. This shows a meaningful difference in approach which has been long needed,” she said.
Roberts said many women already use real-world data from consumer devices to help determine medical issues. This, she said, shows a clear unmet need: “The MHRA has now said it will use real world data to identify differences in medicinal product outcomes for men and women. They will also be looking for sex-disaggregated evidence at every stage in the regulation of medicinal products. This demonstrates an effort to fix the gap and to prevent it developing further going forwards. Companies will need to consider if the data they are collecting for regulatory approval will be sufficient.”
“The MHRA is going to develop clear regulatory frameworks for femtech and related women’s health technologies. This is useful in setting the standard for products which may sit in the wellness space. It could give them a clear pathway to become regulated products to increase access,” she said.
Roberts added that addressing the evidence gap in women’s health is something the MHRA “cannot do alone”. She welcomed the UK regulator’s commitment to drive the agenda globally but called on other regulators, like the European Medicines Agency and US Food and Drugs Administration, to also act, to affect “a larger change”.